ACIP COVID-19 Vaccines Work Group

Dr. Beth Bell, Work Group Chair

February 28, 2021
COVID-19 Work Group activities – February 2021

- COVID-19 Vaccine Work Group meets weekly

- Topics covered:
  - Overview of Adenovirus vector vaccines
  - Clinical development program for Ad26.COV.2 (Janssen) COVID-19 vaccine
  - GRADE/EtR for Janssen COVID-19 vaccine
  - Considerations for the use of COVID-19 vaccines
  - Safety updates
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for use of the Janssen COVID-19 vaccine for the prevention of Coronavirus Disease 2019 (COVID-19) for individuals 18 years of age and older.
Today's Agenda
Sunday, February 28

- Overview of Janssen’s single dose COVID-19 vaccine, Ad26.COV2.S
  Dr. Macaya Douoguih (Janssen Pharmaceuticals Companies of Johnson & Johnson)

- GRADE: Janssen COVID-19 vaccine
  Dr. Julia Gargano (CDC)

- Evidence to Recommendation Framework: Janssen COVID-19 vaccine
  Dr. Sara Oliver (CDC)

- Public Comment

- Discussion

- VOTE:
  Janssen COVID-19 vaccine
Tomorrow's Agenda
Monday, March 1

- Implementation considerations for COVID-19 vaccines
  Dr. Kathleen Dooling (CDC)

- Clinical considerations for use of COVID-19 vaccines
  Ms. Jessica MacNeil (CDC)

- Vaccine Safety Technical Subgroup (VaST) introduction
  Dr. Grace Lee (ACIP, VaST Co-chair)

- COVID-19 Vaccine Safety Update
  Dr. Tom Shimabukuro (CDC)

- VaST assessment of safety data
  Dr. Grace Lee (ACIP, VaST Co-chair)

- Emerging SARS-CoV-2 variants
  Dr. Heather Scobie (CDC)
Work group members

**ACIP members**
- Beth Bell (chair)
- Matthew Daley
- Grace Lee
- Jose Romero
- Keipp Talbot

**Ex-officio/government members**
- FDA: Doran Fink, Rachel Zhang
- NIH: Chris Roberts
- IHS: Thomas Weiser, Uzo Chukwuma
- DOD: Bryan Schumacher
- CMS: Jeff Kelman
- BARDA: Christine Oshansky
- HHS: David Kim

**CDC Co-leads**
- Kathleen Dooling
- Sara Oliver

**Liaisons**
- AAFP: Jonathan Temte
- AAP: Sean O’Leary
- ACOG: Denise Jamieson (primary), Laura Riley (alternate)
- ACP: Jason Goldman
- AGS: Ken Schmader
- AIM: Rob Shechter (primary), Jane Zucker (alternate)
- AMA: Sandra Fryhofer
- ANA: Kendra McMillan (primary), Ruth Francis (alternate)
- APhA: Michael Hogue
- ASTHO: Marcus Plescia
- CSTE: Susan Lett (primary), Christine Hahn (alternate)
- IDSA: Jeff Duchin (primary), Carol Baker (alternate)

**Liaisons, cont’d**
- NACCHO: Matt Zahn (primary), Jeff Duchin (alternate)
- NACI: Matthew Tunis
- NFID: Bill Schaffner (primary), Marla Dalton (alternate)
- NMA: Oliver Brooks
- SHEA: Marci Drees

**Consultants**
- Ed Belongia
- Kathy Kinlaw
- Dayna Matthew
- Kathleen Neuzil
- Stanley Perlman
- Peter Szilagyi
CDC participants

- Amy Blaine
- Doug Campos-Outcalt
- Mary Chamberland
- Thomas Clark
- Amanda Cohn
- Jean Cox-Ganser
- Jonathan Duffy
- Anthony Fiore
- Mark Freedman
- Sue Gerber
- Jack Gersten
- Susan Goldstein
- Sam Graitcer
- Lisa Grohskopf
- Julie Garon
- Stephen Hadler
- Rita Helfand
- Susan Hiers
- Terri Hyde
- Cynthia Jorgensen
- Erin Kennedy
- Sarah Kidd
- Ram Koppaka
- Nicole Lindsey
- Ruth Link-Gelles
- Jessica MacNeil
- Lauri Markowitz
- Mona Marin
- Sarah Mbaeyi
- Nancy Messonnier
- Rebecca Morgan
- Titilope Oduyebo
- Anita Patel
- Janell Routh
- Stephanie Schrag
- Heather Scobie
- Edwin Shanley
- Tom Shimabukuro
- Heidi Soeters
- Mark Sotir
- Stephanie Thomas
- Natalie Thornburg
- Jennifer Verani
- Megan Wallace
- Annemarie Wasley
- Cindy Weinbaum
- Melinda Wharton
- Yon Yu
For more information, contact CDC
1-800-CDC-INFO (232-4636)

Thank you!

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.